{
    "id": 22997,
    "fullName": "EGFR K467T",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR K467T lies within the extracellular domain of the Egfr protein (UniProt.org). K467T results in increased Egfr and Erk phosphorylation and confers resistance to Erbitux (cetuximab) in cell culture (PMID: 26843189).",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "K467T",
    "createDate": "06/01/2016",
    "updateDate": "06/24/2018",
    "referenceTranscriptCoordinates": {
        "id": 135708,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55160240A>C",
        "cDna": "c.1400A>C",
        "protein": "p.K467T",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9311,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR K467T in culture (PMID: 26888827).",
            "molecularProfile": {
                "id": 23656,
                "profileName": "EGFR K467T"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7071,
                    "pubMedId": 26888827,
                    "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26888827"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6639,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines over expressing EGFR K467T were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23656,
                "profileName": "EGFR K467T"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6640,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23656,
                "profileName": "EGFR K467T"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6638,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).",
            "molecularProfile": {
                "id": 23656,
                "profileName": "EGFR K467T"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5719,
                    "pubMedId": 26843189,
                    "title": "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26843189"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23656,
            "profileName": "EGFR K467T",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135710,
            "transcript": "NM_201282",
            "gDna": "chr7:g.55160240A>C",
            "cDna": "c.1400A>C",
            "protein": "p.K467T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135708,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55160240A>C",
            "cDna": "c.1400A>C",
            "protein": "p.K467T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135709,
            "transcript": "NM_201284",
            "gDna": "chr7:g.55160240A>C",
            "cDna": "c.1400A>C",
            "protein": "p.K467T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}